Dallas, TX: ReportsandReports announce Merck KGaA: PharmaVitae Profile Market Research Report in its Store.
Browse complete Report at: http://www.reportsandreports.com/reports/8512-merck-kgaa-pharmavitae-profile.html
This analysis examines the historical and forecast performance for Merck KGaA in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
• Benchmark Merck KGaA’s performance against key rivals in the prescription pharmaceutical sector
• Learn how the continued strong performance of Erbitux will drive the company’s prescription pharma business in the period to 2015
• Evaluate the company’s more focused business strategy and see how its extensive restructuring has affected its operating cost and profit margins
• CHAPTER 1 ABOUT THIS PROFILE 2
• Executive summary 2
Quarterly news update 2
Company introduction 2
Company sales 2
Company financials 2
Key products and competitors 3
Data sourcing 3
Sales data 3
Analyst consensus 3
• CHAPTER 2 EXECUTIVE SUMMARY 4
• Key findings 4
Prescription pharmaceutical sales performance, 2001-13 5
Financial performance, 2001-13 6
Merck KGaA: PharmaVitae forecasts at a glance 7
Strategic insight 8
Erbitux and Serono acquisition rejuvenate branded Rx pharma business 8
and diversify Merck KGaA’s portfolio to improve long-term prospects 9
From pure-play small molecule company to biopharmaceutical 10
Expansion into CNS and oncology 11
Breaking into the US 12
A ‘younger’ product portfolio 13
Re-structuring bolsters financial performance 14
SWOT analysis 17
Strengths 17
Growth prospects of Erbitux 17
Broad portfolio supported by pipeline 18
Continued sales growth from off-patent products 18
Weaknesses 18
Over reliance on Erbitux to drive growth 18
Opportunities 19
Expansion of oncology portfolio through continued growth of Erbitux and development of pipeline candidates 19
Continued improvement of operating profit margin 19
Use high revenues to pursue licensing deals to further bolster portfolio 20
Pursue M&A opportunities to build consumer health and life sciences businesses 20
Threats 20
Increasing competition from biosimilars is affecting the growth prospects of Merck KGaA’s therapeutic protein franchise 20
• CHAPTER 3 QUARTERLY NEWS UPDATE 25
• Product developments 25
Deals and alliances 26
Product deals 26
Technology deals 31
M&A activity 33
Company announcements 34
Future product milestones 38
• CHAPTER 4 COMPANY INTRODUCTION 39
• Key findings 39
Background 40
Key corporate developments 40
M&A history 41
Merck-Serono Biopharmaceuticals 41
Divestment of generics business 41
Streamlined focus 42
Current corporate structure 42
Pharmaceuticals 43
Branded prescription pharmaceuticals 43
Consumer health 43
Chemicals 44
Performance & life science chemicals 44
Liquid crystals 44
Pharmaceuticals business unit structure 45
• CHAPTER 5 COMPANY SALES 46
• Key findings 46
Prescription pharmaceutical sales and growth rate analysis, 2001-13 48
Product analysis 50
Product analysis, 2001-07 50
Product analysis, 2007-13 53
Therapy area analysis 56
Therapy area analysis, 2001-07 57
Therapy area analysis, 2007-13 59
Therapy area focus, 2001-13 61
Geographic analysis 63
Geographic analysis, 2001-07 64
Geographic analysis, 2007-13 66
Geographic focus, 2001-13 68
Launch/core/expiry analysis 69
Explanation of launch/core/expiry analysis 69
Launch analysis, 2007-13 70
Core analysis, 2007-13 71
Expiry analysis, 2007-13 72
Launch/core/expiry configuration, 2007-13 73
Molecule type analysis 75
Molecule type analysis, 2001-07 76
Molecule type analysis, 2007-13 77
Externalization analysis 79
Externalization analysis, 2001-07 80
Externalization analysis, 2007-13 81
• CHAPTER 6 COMPANY FINANCIALS 83
• Key findings 83
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07 84
Financial statements, 2001-07 86
Profit and loss account, 2001-07 86
Balance sheet, 2001-07 88
Operating costs and profit analysis 90
Operating costs and profit analysis, 2001-07 91
Operating cost ratio and profit margin analysis, 2001-07 92
Operating cost ratio and profit margin analysis, 2007-13 93
Operating costs and profit analysis, 2007-13 95
Return on capital employed analysis 97
Capital employed analysis, 2001-07 98
Return on capital employed (RoCE) analysis, 2001-07 100
Market capitalization analysis 103
Market capitalization analysis, 2001-07 103
Total shareholder returns analysis, 2001-07 104
• CHAPTER 7 KEY PRODUCTS AND COMPETITORS 106
• Key findings 106
Overview 107
CNS 108
Rebif 108
Overview 108
Sales forecast 109
Mylinax 113
Overview 113
Sales forecast 114
safinamide 117
Overview 117
Sales forecast 118
Oncology 121
Erbitux 121
Overview 121
Sales forecast 122
Cardiovascular 124
Concor & Concor-Plus 124
Overview 124
Sales forecast 125
Kuvan 126
Overview 126
Sales forecast 127
Urology & gender-specific health 128
Gonal-F 128
Overview 128
Sales forecast 129
Endocrine, metabolic and genetic disorders 132
Glucophage & Glucovance 132
Overview 132
Sales forecast 133
• CHAPTER 8 APPENDIX 134
• R&D pipeline 134
References 135
Papers 135
Company releases 135
Datamonitor reports 135
News articles 136
Abbreviations 136
Exchange rates 137
ABBREVIATIONS
Browse all : Healthcare Market Research Reports
http://www.reportsandreports.com/cat/healthcare-market-research.html
Browse all : Datamonitor Market Research Reports
http://www.reportsandreports.com/Publisher/datamonitor-market-research.html-market-research.html
Browse all Newly Published Market Research Reports
http://www.reportsandreports.com/LatestReport.aspx
Original Source : PharmaVitae Market
http://www.reportsandreports.com/reports/8512-merck-kgaa-pharmavitae-profile.html
Buy Now : Market Research Report
http://www.reportsandreports.com/
Related Reports:
Merck & Co. Inc: PharmaVitae Profile
http://www.reportsandreports.com/reports/8184-merck-co-inc-pharmavitae-profile.html
Merck KGaA-Detailed Product Pipeline
http://www.reportsandreports.com/reports/30214-merck-kgaa-detailed-product-pipeline.html
Merck KGaA-Company Report
http://www.reportsandreports.com/reports/5761-merck-kgaa-company-report.html
Merck KGaA-Deals & Alliances Report
http://www.reportsandreports.com/reports/32118-merck-kgaa-deals-alliances-report.html
Merck KGaA – SWOT Analysis
http://www.reportsandreports.com/reports/1960-merck-kgaa-swot-analysis.html
About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
